TransThera-B (02617.HK): Jienertai (tinengotinib) included in the CSCO Guidelines for the Diagnosis and Treatment of Biliary Tract Malignancies (2026)

Zhitong Finance APP News, TransThera-B (02617.HK) announced that the "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Biliary Tract Malignancies" (hereinafter referred to as the Guidelines) has been officially released, and Jienertai (tinengotinib), an innovative multi-target small molecule kinase inhibitor independently developed by the Company, has been included in the Guidelines as a Class II recommendation, Category 2A for the treatment of advanced biliary tract malignancies.